Gilead Sciences, Inc. vs Trip.com Group Ltd — how do they compare? Gilead Sciences, Inc. trades at $134.55 (market cap $163.51B), while Trip.com Group Ltd trades at $43.86 (market cap $26.95B). The key difference: Gilead Sciences, Inc. is far larger — about 6.1× Trip.com Group Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TCOM | |
|---|---|---|
Market Cap | $163.51B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $78.96 |
52-Week Low | $108.22 | $39.84 |
Enterprise Value | $178.05B | $19.65B |
Dividend Yield | 2.49% | 0.42% |
Trailing returns across standard periods
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →